WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.

Item

http://www.wikidata.org/entity/Q38187457

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

WT1 vaccination in acute myelo ...... enting adoptive immunotherapy.

@en

type

Item

label

WT1 vaccination in acute myelo ...... enting adoptive immunotherapy.

@en

prefLabel

WT1 vaccination in acute myelo ...... enting adoptive immunotherapy.

@en

P1476

WT1 vaccination in acute myelo ...... enting adoptive immunotherapy.

@en

P2093

Lindsay A M Rein

http://www.w3.org/2001/XMLSchema#string

Nelson J Chao

http://www.w3.org/2001/XMLSchema#string

P2860

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

WT1 proteins: functions in growth and differentiation

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells.

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemot

P304

417-426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.889114

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24521058

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy